$58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing
$58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing
$5800万美元并购：Chain Bridge I收购大麻类药物创新公司，计划上市纳斯达克
Chain Bridge I (NASDAQ:CBRG) announced on Monday the acquisition of Phytanix Bio, a pharmaceutical company specializing in the development of therapeutics based on cannabinoid and cannabinoid-like molecules. The transaction, valued at $58 million, also includes the assumption of preferred stock and short-term debt, which will convert to preferred stock upon the deal's closure, slated for the fourth quarter of 2024.
Chain Bridge I（纳斯达克：CBRG）于星期一宣布，收购专门从事以大麻素和类大麻素分子为基础的治疗方案开发的药品公司Phytanix Bio。这笔交易价值$5800万，还包括优先股和短期债务的承担，将在交易的结束时转换为优先股，预计于2024年第四季度结束。
Phytanix Bio's Strategic Acquisition Overview
Phytanix Bio的战略收购概述
Phytanix Bio, a company founded by former GW Pharmaceuticals leaders, holds exclusive intellectual property that has been central to the creation of FDA-approved cannabinoid-based medicines like Sativex and Epidiolex. With...
由前GW Pharmaceuticals领导人创立的公司Phyt...
登录免费看全文
登录/注册